A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas Benjamin Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Andreas Goutopoulos, Anne Moon, Yonchu Jenkins, Peppi Prasit, Thomas Walter Dubensky, Sam H. Whiting, Susanna Varkey Ulahannan
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Carolina BioOncology Institute, Abramson Cancer Center, University of Pennsylvania, Michigan Medicine, University of California, San Francisco, Sarah Cannon, Tennessee Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Columbia University Irving Medical Center, Columbia University, OU Health Stephenson Cancer Center, University of Oklahoma
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286295223